Ray (228670) Fundamentals 2026 — P/E 21.1x, Revenue Analysis | SniperIQ
Ray (228670) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩75.0B, trading at ₩4810.00 on the KOE. This SniperIQ fundamentals page covers Ray's valuation (P/E 21.1x, P/B 0.9x), profitability (net margin 3.2%), revenue (₩111.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ray's market cap?
Ray (228670) has a market capitalization of approximately ₩75.0B, trading at ₩4810.00 on the KOE. Market cap moves with the live share price.
What is Ray's P/E ratio?
Ray's trailing twelve-month P/E ratio is 21.1x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ray?
Ray runs a net profit margin of 3.2%, a gross margin of 40.7%, and an operating margin of -11.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ray generate?
Ray reported revenue of ₩111.2B for fiscal year 2025, with net income of ₩3.1B and earnings per share (EPS) of 200.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ray pay a dividend?
Ray does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Ray financially healthy?
Ray carries a debt-to-equity ratio of 0.83x and a current ratio of 1.32x, with a market beta of 1.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ray a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ray (228670) the key facts are: market cap ₩75.0B, P/E 21.1x, revenue ₩111.2B, 52-week range 3975-11690. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ray's full fundamentals live
Get Ray's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.